Navigation Links
Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations

MURRIETA, Calif., Aug. 27 /PRNewswire/ -- Despite tough economic times, Copan is proud to announce the expansion of its US operations. Copan Diagnostics, Inc. is undertaking a new multimillion dollar investment project to bring plastic transfer pipet and additional medical device manufacturing operations to its facility in Murrieta, California. The expansion plan includes the addition of blow molding machinery and filling and packing equipment to expand Copan's current capabilities.

To support the expansion, Copan purchased a 13,000 sq ft building adjacent to its current facility to house new plastic blow molding equipment used to manufacture transfer pipets. The new building allows the transfer of some activities from its current location freeing up space to expand medical device manufacturing operations for the company's microbiology specimen collection and transport line. The project is an integral part of Copan's corporate wide plan to support future demand. Norman Sharples, Executive VP, says that "in today's market, companies must examine opportunities to bring further efficiencies to their operations to remain competitive, which is what we are doing with this endeavor."

Plastic transfer pipets are an essential product widely used by hospital, research and industrial laboratories for transferring liquids and clinical samples during diagnostics testing or analytical research. In fact, as many as 500 million pipets are used in the USA annually. Copan has manufactured pipets at its Italian headquarters for over 25 years, and it has developed a customized blow molding equipment that maximizes productivity through a fully automated system for separating molded product from waste material, which is then 100% recycled.

The efficient technology developed and tuned at Copan Italia is now transferred to California. "The decision to bring manufacturing of this product line locally is to be able to bring the product closer to our customers to respond rapidly to their needs," Sharples adds. The initial phase of manufacture will focus on the three most popular pipets: 1ml, 3ml and Blood Banking pipets. During this phase, Copan will produce 300,000 pipets daily with plans to increase production in 2010.

"Copan is excited about this new venture as it greatly expands the capabilities of our US operation and allows Copan to enhance service to our customers. This expansion also marks the 15th anniversary of Copan's operations in the US," Sharples concludes.

About Copan Diagnostics, Inc.

With a reputation for innovation in preanalytics, Copan Diagnostics is the leading manufacturer of collection and transport systems in the world. Copan offers a complete range of microbial sampling products used for traditional culture analysis and for molecular diagnostic assays, as well as producing innovations, like the patented Flocked Swabs, Universal Transport Medium and ESwab. The company manufactures a comprehensive line of laboratory consumables comprising of inoculation loops, needles, spreaders and transfer pipets. Copan also produces WASP: Walk-Away Specimen Processor, a revolutionary system for automatic planting and streaking of microbiology samples. For more information about Copan, visit

SOURCE Copan Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim
2. Vancouver General Hospital is the First Canadian Institution to Implement Copan WASP(R): Walk-Away Specimen Processor
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):